Contact this trialFirst, we need to learn more about you.
Tumor Necrosis Factor (TNF) Inhibitor
Upadacitinib vs. Adalimumab for Psoriatic Arthritis
Recruiting3 awardsPhase 3
Phoenix, Arizona
This trial will compare the effectiveness of two doses of a new drug, upadacitinib, to a placebo and to the drug adalimumab, in people with psoriatic arthritis who have not responded well to other treatments. The trial will also look at the long-term safety and effectiveness of upadacitinib.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.